Search Results

EpicGenetics announced a contract with the Mayo Clinic Fibromyalgia and Chronic Fatigue Clinic to perform research to investigate the use of the EpicGenetics FM/a® Test to determine the test’s use and applicability to objectively diagnose fibromyalgia

A recently published study of thousands of fibromyalgia patients illuminates a pathway to preventing the life-threatening pneumonia, lung damage and immunologic complications that can be caused by a COVID-19 infection, according to EpicGenetics Inc., which funded and conducted the research with the University of Illinois College of Medicine at Chicago’s Department of Pathology.

EpicGenetics to offer a no-fee immune system COVID-19 FDA-authorized antibody test with every FM/a® Test

EpicGenetics, the biomedical company that developed and offers the FM/a Test, the FDA-compliant diagnostic blood test that identifies the immune system biomarkers of fibromyalgia, moved into a new facility that quadruples its capacity

EpicGenetics and Massachusetts General Hospital (MGH) are launching a Phase II clinical trial to test a tuberculosis vaccine, BCG, as a potential treatment for fibromyalgia.

EpicGenetics, the biomedical company that developed and offers the FM/a Test, the FDA-compliant diagnostic blood test that identifies the immune system biomarkers of fibromyalgia, today announced a 50 percent growth in applications for the test.

The biomedical company addresses requirements in response to surge of inquiries

After analyzing thousands of patients, EpicGenetics today announced that its data shows that 80 percent of young people (under 19 years of age) who were tested for fibromyalgia were previously misdiagnosed with attention deficit hyperactivity disorder (ADHD).

The FM/a Test is the first and only objective, FDA-compliant blood test to provide a definitive diagnosis for fibromyalgia.